Tislelizumab Combined With Anlotinib And Chemotherapy (SOX) In Neoadjuvant Therapy For Locally Advanced Adenocarcinoma Of Esophagogastric Junction
Conditions: Immunotherapy Gastroesophageal Junction Interventions: Drug: Tislelizumab; Drug: Anlotinib; Drug: Oxaliplatin; Drug: Tegafur Sponsors: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 2, 2024 Category: Research Source Type: clinical trials
Organ Preservation With Tislelizumab and Total Neoadjuvant Therapy in Patients With Low Rectal Cancer: RELIEVE -01 Study
Conditions: RECTAL NEOPLASMS; Rectal Cancer Interventions: Radiation: Radiotherapy; Drug: Tislelizumab; Drug: Capecitabine; Drug: Oxaliplatin; Drug: Capecitabine Sponsors: Fudan University; Shanghai Zhongshan Hospital; Shanghai Changzheng Hospital; Huadong Hospital; RenJi Hospital; The Fourth Hospital of Hebei Medical University; First Hospital of China Medical University; Liaoning Cancer Hospital& Institute Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials
Irinotecan Liposome II in Combination With 5-FU/LV and Oxaliplatin in Perioperative Treatment of Borderline Resectable Pancreatic Cancer
Conditions: Borderline Resectable Pancreatic Cancer Interventions: Drug: irinotecan liposome II combined with 5-FU/LV and oxaliplatin Sponsors: Peking Union Medical College Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 29, 2024 Category: Research Source Type: clinical trials
HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer
Conditions: Efficacy and Safety Interventions: Drug: HR070803; Drug: Oxaliplatin; Drug: Tegafur; Drug: Folinic acid; Drug: 5-Fluorouracil Sponsors: The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 25, 2024 Category: Research Source Type: clinical trials
Photoradiation With Verteporfin to Facilitate Immunologic Activity of Pembrolizumab in Unresectable, Locally Advance or Metastatic Pancreatic Cancer
Conditions: Locally Advanced Pancreatic Adenocarcinoma; Metastatic Pancreatic Adenocarcinoma; Stage II Pancreatic Cancer AJCC v8; Stage III Pancreatic Cancer AJCC v8; Stage IV Pancreatic Cancer AJCC v8; Unresectable Pancreatic Adenocarcinoma Interventions: Procedure: Biopsy; Procedure: Biospecimen Collection; Procedure: Computed Tomography; Procedure: Endoscopic Ultrasound; Drug: Fluorouracil; Drug: Irinotecan; Drug: Leucovorin; Procedure: Lymph Node Biopsy; Procedure: Magnetic Resonance Imaging; Drug: Oxaliplatin; Biological: Pembrolizumab; Drug: Photodynamic Therapy; Procedure: Positron Emission Tomography; Other: Questi...
Source: ClinicalTrials.gov - April 24, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
Conditions: Colon Cancer Interventions: Drug: Serplulimab; Drug: Capecitabine; Drug: Oxaliplatin Sponsors: Ruijin Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Irinotecan Liposome Combined With Oxaliplatin and Tegafur as Adjuvant Therapy for Pancreatic Cancer
Conditions: Pancreatic Cancer; Adjuvant Therapy Interventions: Drug: Irinotecan liposome injection Sponsors: Kuirong Jiang; CSPC Ouyi Pharmaceutical Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 11, 2024 Category: Research Source Type: clinical trials
A Randomized, Multicenter Phase II Basket Study of Hypofractionated Radiotherapy/Stereotactic Body Radiotherapy Followed by Immunotherapy-Based Systemic Therapy +/- L. Rhamnosus M9 for the First-Line Treatment of Advanced Digestive System Malignancies.
Conditions: Gastroesophageal Junction Adenocarcinoma; Liver Cancer Stage IV; Biliary Tract Cancer; Pancreatic Adenocarcinoma; Colorectal Cancer; Gastric Cancer Interventions: Radiation: Hypofractionated radiotherapy/SBRT （5-8 Gy/fx，3-5 fx）; Drug: Anti-PD-1 monoclonal antibody; Drug: Oxaliplatin and Capecitabine; Drug: Anti-VEGF 15mg/kg; Drug: Anti-VEGF 7.5mg/kg; Drug: Gemcitabine and Cisplatin; Drug: Gemcitabine and Albumin paclitaxel Sponsors: Zhejiang Cancer Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 5, 2024 Category: Research Source Type: clinical trials
NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study
Conditions: Borderline Resectable Pancreatic Cancer Interventions: Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate in combination with Camrelizumab; Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences; Jiangsu HengRui Medicine Co., Ltd. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 3, 2024 Category: Research Source Type: clinical trials
Concurrent Chemoradiotherapy Combined With Sintilimab as Neoadjuvant Therapy for GC Patients With PALM
Conditions: Gastric Cancer; Gastric Cancer Metastatic to Regional Lymph Nodes Interventions: Drug: Sintilimab; Radiation: Extraperitoneal radiation therapy; Drug: Oxaliplatin; Drug: S-1 Sponsors: The First Affiliated Hospital with Nanjing Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 2, 2024 Category: Research Source Type: clinical trials
A Phase II Multicenter Clinical Study of Improved Short-course Radiotherapy Combined With CAPOX and PD-1 Monoclonal Antibody for Locally Advanced Mid-low Rectal Cancer
Conditions: Mid-low Rectal Cancer Interventions: Radiation: Short-course Radiotherapy; Drug: Tislelizumab; Drug: capecitabine; Drug: Oxaliplatin Sponsors: Fujian Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 27, 2024 Category: Research Source Type: clinical trials
ELVN-002 With Trastuzumab +/- Chemotherapy in HER2+ Solid Tumors, Colorectal and Breast Cancer
Conditions: HER2-positive Breast Cancer; HER2-positive Gastric Cancer; HER2 Positive Solid Tumors; HER2 Amplification; Colorectal Cancer Interventions: Drug: ELVN-002; Drug: Trastuzumab; Drug: 5-Fluorouracil; Drug: Oxaliplatin; Drug: Capecitabine; Drug: Eribulin; Drug: paclitaxel; Drug: Leucovorin Sponsors: Enliven Therapeutics Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 25, 2024 Category: Research Source Type: clinical trials
Comparing the Safety and Efficacy of First-line Polychemotherapy and Polychemotherapy in Combination With PIPAC Sessions
Conditions: Gastric Cancer Interventions: Drug: Docetaxel; Drug: Oxaliplatin; Drug: Calcium folinate; Drug: Fluorouracil; Procedure: Diagnostic laparoscopy; Combination Product: dPIPAC ( The description of the standard diagnostic laparoscopy procedure and the session of PIPAC (dPIPAC)). Sponsors: Nizhny Novgorod Regional Clinical Oncology Center Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Neoadjuvant Cadonilimab Plus Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer Trial
Conditions: Gastric Cancer; Esophagogastric Junction Cancer Interventions: Drug: Cadonilimab; Drug: Oxaliplatin; Drug: Capecitabine Sponsors: Nanfang Hospital, Southern Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
Surufatinib Combined With Toripalimab and HAIC in the Treatment of Inoperable or Metastatic Intrahepatic Cholangiocarcinoma
Conditions: Intrahepatic Cholangiocarcinoma Interventions: Drug: Surufatinib 、Toripalimab、Gemcitabine、Oxaliplatin Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2024 Category: Research Source Type: clinical trials
